These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

409 related articles for article (PubMed ID: 30890362)

  • 1. ADMET modeling approaches in drug discovery.
    Ferreira LLG; Andricopulo AD
    Drug Discov Today; 2019 May; 24(5):1157-1165. PubMed ID: 30890362
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The application of in silico drug-likeness predictions in pharmaceutical research.
    Tian S; Wang J; Li Y; Li D; Xu L; Hou T
    Adv Drug Deliv Rev; 2015 Jun; 86():2-10. PubMed ID: 25666163
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Predictive QSAR modeling for the successful predictions of the ADMET properties of candidate drug molecules.
    Khan MT; Sylte I
    Curr Drug Discov Technol; 2007 Oct; 4(3):141-9. PubMed ID: 17985997
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Informing the Selection of Screening Hit Series with in Silico Absorption, Distribution, Metabolism, Excretion, and Toxicity Profiles.
    Sanders JM; Beshore DC; Culberson JC; Fells JI; Imbriglio JE; Gunaydin H; Haidle AM; Labroli M; Mattioni BE; Sciammetta N; Shipe WD; Sheridan RP; Suen LM; Verras A; Walji A; Joshi EM; Bueters T
    J Med Chem; 2017 Aug; 60(16):6771-6780. PubMed ID: 28418656
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Model-based Target Pharmacology Assessment (mTPA): An Approach Using PBPK/PD Modeling and Machine Learning to Design Medicinal Chemistry and DMPK Strategies in Early Drug Discovery.
    Chen EP; Bondi RW; Michalski PJ
    J Med Chem; 2021 Mar; 64(6):3185-3196. PubMed ID: 33719432
    [TBL] [Abstract][Full Text] [Related]  

  • 6. In silico ADME-Tox modeling: progress and prospects.
    Alqahtani S
    Expert Opin Drug Metab Toxicol; 2017 Nov; 13(11):1147-1158. PubMed ID: 28988506
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comprehensive assessment of ADMET risks in drug discovery.
    Wang J
    Curr Pharm Des; 2009; 15(19):2195-219. PubMed ID: 19601823
    [TBL] [Abstract][Full Text] [Related]  

  • 8. ADMET--Fifth Annual SMi Conference.
    Comer JE
    IDrugs; 2010 Sep; 13(9):610-4. PubMed ID: 20799141
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Modeling ADMET.
    Ghosh J; Lawless MS; Waldman M; Gombar V; Fraczkiewicz R
    Methods Mol Biol; 2016; 1425():63-83. PubMed ID: 27311462
    [TBL] [Abstract][Full Text] [Related]  

  • 10. De-risking drug discovery with ADDME -- avoiding drug development mistakes early.
    Tsaioun K; Jacewicz M
    Altern Lab Anim; 2009 Sep; 37 Suppl 1():47-55. PubMed ID: 19807206
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Bayer's in silico ADMET platform: a journey of machine learning over the past two decades.
    Göller AH; Kuhnke L; Montanari F; Bonin A; Schneckener S; Ter Laak A; Wichard J; Lobell M; Hillisch A
    Drug Discov Today; 2020 Sep; 25(9):1702-1709. PubMed ID: 32652309
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Machine Learning for In Silico ADMET Prediction.
    Jia L; Gao H
    Methods Mol Biol; 2022; 2390():447-460. PubMed ID: 34731482
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Recent progresses in the exploration of machine learning methods as in-silico ADME prediction tools.
    Tao L; Zhang P; Qin C; Chen SY; Zhang C; Chen Z; Zhu F; Yang SY; Wei YQ; Chen YZ
    Adv Drug Deliv Rev; 2015 Jun; 86():83-100. PubMed ID: 26037068
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A Recent Appraisal of Artificial Intelligence and In Silico ADMET Prediction in the Early Stages of Drug Discovery.
    Kumar A; Kini SG; Rathi E
    Mini Rev Med Chem; 2021; 21(18):2788-2800. PubMed ID: 33797376
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Two-dimensional (2D) in silico models for absorption, distribution, metabolism, excretion and toxicity (ADME/T) in drug discovery.
    Khakar PS
    Curr Top Med Chem; 2010; 10(1):116-26. PubMed ID: 19929825
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Integrating in vitro ADMET data through generic physiologically based pharmacokinetic models.
    Leahy DE
    Expert Opin Drug Metab Toxicol; 2006 Aug; 2(4):619-28. PubMed ID: 16859409
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacokinetic properties and in silico ADME modeling in drug discovery.
    Honório KM; Moda TL; Andricopulo AD
    Med Chem; 2013 Mar; 9(2):163-76. PubMed ID: 23016542
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Predictive Modelling in pharmacokinetics: from in-silico simulations to personalized medicine.
    Paliwal A; Jain S; Kumar S; Wal P; Khandai M; Khandige PS; Sadananda V; Anwer MK; Gulati M; Behl T; Srivastava S
    Expert Opin Drug Metab Toxicol; 2024 Apr; 20(4):181-195. PubMed ID: 38480460
    [TBL] [Abstract][Full Text] [Related]  

  • 19. ADMET evaluation in drug discovery. 11. PharmacoKinetics Knowledge Base (PKKB): a comprehensive database of pharmacokinetic and toxic properties for drugs.
    Cao D; Wang J; Zhou R; Li Y; Yu H; Hou T
    J Chem Inf Model; 2012 May; 52(5):1132-7. PubMed ID: 22559792
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Optimizing DMPK Properties: Experiences from a Big Pharma DMPK Department.
    Sohlenius-Sternbeck AK; Janson J; Bylund J; Baranczewski P; Breitholtz-Emanuelsson A; Hu Y; Tsoi C; Lindgren A; Gissberg O; Bueters T; Briem S; Juric S; Johansson J; Bergh M; Hoogstraate J
    Curr Drug Metab; 2016; 17(3):253-70. PubMed ID: 26651977
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.